Core Viewpoint - The appointment of Zhao Lei as a co-manager for the China Europe Medical Health Fund signifies a trend towards multi-manager collaboration in the pharmaceutical fund sector, enhancing management capabilities and investment strategies [2][4][6]. Group 1: Fund Management Changes - Zhao Lei has been appointed as a co-manager alongside Ge Lan for the China Europe Medical Health Mixed Fund, while Ge Lan will continue to manage other products independently [2][4]. - Zhao Lei has over 8 years of experience in the pharmaceutical and biotechnology sector and has held various research roles before joining China Europe Fund in 2021 [4]. - As of the end of Q1 this year, Ge Lan managed three funds with a total scale of 404.47 billion yuan, with the China Europe Medical Health Fund achieving a net value growth rate of 8.30% in the first half of the year, outperforming the CSI Pharmaceutical Index by 6.03% [4]. Group 2: Performance Metrics - The China Europe Medical Innovation Fund, also managed by Ge Lan, reported a 32.25% growth in the last six months, with an excess return of 26.8% compared to its benchmark, ranking in the top 4% of its category [5]. - Over the past year, the same fund achieved a growth of 51.63%, with a 37.17% excess return relative to its benchmark, maintaining a top 4% ranking [5]. - The China Europe Index products, including the China Europe CSI Hong Kong Stock Connect Innovative Drug Index, have also shown strong performance, with a 50.94% increase in the last six months, ranking in the top 1% of its category [5]. Group 3: Industry Trends - The trend of multi-manager collaboration is becoming a significant transformation direction in the public fund industry, with 666 products undergoing co-management appointments in the first half of the year [7]. - This collaborative model allows for better utilization of each manager's strengths, enhancing the risk-return profile of the investment portfolio [7]. - Regulatory bodies are promoting a shift towards team-based management structures, emphasizing the importance of building robust research capabilities and moving away from reliance on star fund managers [8]. Group 4: Company Strategy - China Europe Fund is focused on strengthening its research team and investment capabilities, with an average financial industry experience of 14 years among its active equity fund managers [8]. - The company aims to create a stable, expert research team that covers 39 niche areas through in-depth research, supporting its investment strategies [8].